The US biosimilar market is developing, but its sustainability in the market is still unknown, according to Amanda Forys, MSPH, director of Xcenda’s Reimbursement Policy Insights consulting team.
The US biosimilar market is developing, but its sustainability in the market is still unknown, according to Amanda Forys, MSPH, director of Xcenda’s Reimbursement Policy Insights consulting team.
Transcript (slightly modified)
Is the US biosimilar market developing how you expected it would?
Yes and no. The biosimilar market in the United States is a bit behind the rest of the world in terms of product availability. We’re getting a lot of lessons learned in seeing what’s going on in the European Union. But, the market here is starting to grow and starting to develop.
We are on the trajectory to have a lot of biosimilars come to market soon, we are just not there yet. There’s a lot of movement around oncology and rheumatoid arthritis products that’s really the big movement on biosimilars in the United States. We’re going to see a lot of products coming out for your typical Remicade, Humira, Enbrel, and Rituxan. Those are the 4 biggies that manufacturers are targeting in their biosimilar development.
The biggest concern with biosimilars coming to the market, and one of the things I work a lot in with our clients, is concern around the stability of the market and where we think it can go in the future. So, while we have got products coming to market there is a lot of concern around reimbursement and policy and coverage for these products and if it will be sustainable in the future. So, while we are growing and while we are developing and having all these products come in, we are not quite sure if we are going to have a market sustainable to keep them and keep manufacturers interested in pursuing that pipeline to get those products out into the market.
The biosimilars market is a bit different from the generics market. A lot of payers, a lot of people, or when you hear Medicare or MedPAC policy, or people coming out and talking about biosimilars—a lot of them get the concept that they are a little bit different from a generic and that it’s not an exact replica of its original product because you cannot make a replica of a living organism like when you create a biosimilar. Because of that, the pathway for approval can take a lot longer and be a lot more expensive. So, instead of the generics market where we are looking at a 3 to 5 year time investment to create a generic that is a $1-2 million cost for the developer to put to the market, biosimilars are an 8 to 10 year development time with a $100 million to $200 million investment. That can be pretty hefty price tag for this market and with a lot of the reimbursement challenges manufacturers may not be willing to go through this pathway for coverage or for the development of these products and that could, down the road—5, 10, 15 years from now—really slow down that pipeline.
I think we are there in that we want to have them in the market and I think people understand the value of them and the economics. Since everyone is talking cost and everyone is talking value, that’s there. But if we can put the right parameters around them to actually encourage that development and the subsequent uptake, that will really be where we are to determine if the US biosimilar market is vibrant like we are seeing elsewhere.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More